Google
MLYS — MINERALYS THERAPEUTICS, INC. COMMON STOCK (Healthcare >> Biotechnology)
MLYS FAQ
What is MLYS's ROE?
MINERALYS THERAPEUTICS, INC. COMMON STOCK reports a Return on Equity (ROE) of -23.78%.
What is MLYS's dividend yield?
MINERALYS THERAPEUTICS, INC. COMMON STOCK offers a dividend yield of 0.00%.
What is MLYS's Deepscope Quality Score?
Deepscope rates MLYS's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy MLYS?
Deepscope's AI Timing Score for MLYS is 55 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does MLYS belong to?
MINERALYS THERAPEUTICS, INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 25.06
Price
-3.79
(-13.14%)
Day Change
|
|
|---|
MLYS, the overall quality is not good ( Quality = 46) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 25.06 |
| PBV / Sector |
3.73 / 4.48
|
| Earning Per Share | -1.60 |
| PE / Sector |
N/A / 16.68
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
42.33 M
GREAT
|
| Average 1W Daily Value |
69.82 M
|
| Timing Factors |
|
28% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-04 09:24:17 |
| Symbol | MLYS |
| Name | MINERALYS THERAPEUTICS, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 82.50 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 2,380.07 / 8,483.11 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 150 N. Radnor Chester Road, Radnor, PA, United States, 19087
Phone: 888 378 6240
Website: https://mineralystx.com
Employees: 76
Sector: Healthcare >> Biotechnology
Description: Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
